A Phase 2 Open Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; Cetirizine; Dexamethasone; Diphenhydramine; Montelukast; Paracetamol
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 Oct 2019 Planned End Date changed from 1 Feb 2020 to 1 Jun 2020.
- 23 Oct 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Jun 2020.
- 25 Jul 2019 Status changed from not yet recruiting to recruiting.